Dynavax Technologies Corporation

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing vaccines in the United States and internationally. Its product HEPLISAV-B is a hepatitis B vaccine for adults aged 18 and older, and its CpG 1018 adjuvant is used in HEPLISAV-B. The company also develops rF1V, a Phase 2 plague vaccine candidate, and Z-1018, a Phase 1/2 shingles vaccine candidate for adults aged 50 and older, as well as HEPLISAV-B for adults on hemodialysis. It sells to hospitals, clinics, public health clinics, prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors, and has collaboration agreements with the U.S. Department of Defense, the Coalition for Epidemic Preparedness Innovations, Zhejiang Clover Biopharmaceuticals, Clover Biopharmaceuticals (Hong Kong), and Biological E. Limited. Formerly known as Double Helix Corporation, it changed its name to Dynavax Technologies Corporation in September 1996, was incorporated in 1996, and is headquartered in Emeryville, California.

DVAX▼

Zacks Adds BMW, DXC Technology, Dynavax to Strong Sell List

Zacks Investment Research added three stocks to its Zacks Rank #5 (Strong Sell) List today. Bayerische Motoren Werke Aktiengesellschaft saw its current-year earnings consensus estimate revised 8.2% downward over the last 60 days. DXC Technology Company's estimate was revised 18.2% downward, and Dynavax Technologies Corporation's estimate was revised 50% downward over the same period.

BMW.XETRA ▼DVAX ▼DXC ▼

BMW.XETRA · Capital · Negative Earnings consensus estimate revised 8.2% downward over the last 60 days

DVAX · Capital · Negative Earnings consensus estimate revised 50% downward over the last 60 days

DXC · Capital · Negative Earnings consensus estimate revised 18.2% downward over the last 60 days

Read original ↗

Zacks Investment Research·88dRead more →